A Multicenter, Randomized, Double-blind, Parallel Group Study to Assess the Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients Comparing Two Titration Regimens
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Adverse reactions; Pharmacodynamics
- Acronyms TITRATION
- Sponsors Novartis; Novartis Pharma A.G.
- 07 Jun 2017 Biomarkers information updated
- 12 May 2016 Results published in the European Journal of Heart Failure
- 24 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.